ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Adamis Pharmaceuticals Corporation

11682 El Camino Real
Suite 300
San Diego, CA 92130
United States

IndustryDrug Delivery
Full Time Employees93

Key Executives

Mr. Richard C. WilliamsChairman and Consultant128kN/A73
Dr. Dennis J. Carlo Ph.D.Chief Exec. Officer, Pres and Director746.28kN/A74
Mr. Robert O. HopkinsChief Financial Officer, VP of Fin. and Sec.369.98kN/A57
Mr. David J. MarguglioChief Bus. Officer, Sr. VP and Director395.53kN/A47
Mr. Robert B. RothermelConsultant and Director64kN/A73
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

Corporate Governance

Adamis Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.